論文發表

2020年:

Successful application of anti-CD19 CAR-T therapy with IL-6 knocking down to patients with central nervous system B-cell acute lymphocytic leukemia

Li-Yun Chen, Li-Qing Kang, Hai-Xia Zhou, Han-Qing Gao, Xue-Fei Zhu, Nan Xu, Lei Yu, De-Pei Wu, Sheng-Li Xue, Ai-Ning Sun.

  Transl Oncol. 2020 Nov;13(11):100838.doi: 10.1016/j.tranon.2020.100838.


Feasibility study of 68 Ga-labeled CAR T cells for in vivo tracking using micro-positron emission tomography imaging

Xin-Yu Wang, Yan Wang, Qiong Wu, Jing-Jing Liu, Yu Liu, Dong-Hui Pan, Wei Qi, Li-Zhen Wang, Jun-Jie Yan, Yu-Ping Xu, Guang-Ji Wang, Li-Yan Miao, Lei Yu, Min Yang.

  Acta Pharmacol Sin. 2020 Sep 8. doi: 10.1038/s41401-020-00511-5.


Secondary donor-derived humanized CD19-modified CAR-T cells induce remission in relapsed/refractory mixed phenotype acute leukemia after allogeneic hematopoietic stem cell transplantation: a case report

Meng-Yun Li, Zhi-Hong Lin, Ming-Ming Hu, Li-Qing Kang, Xiao-Xia Wu, Qi-Wei Chen, Xin Kong, Jian Zhang, Hui-Ying Qiu, De-Pei Wu.

  Biomark Res. 2020 Aug 31;8:36. doi: 10.1186/s40364-020-00216-1.


CAR-T therapy bridging to allogeneic HSCT provides durable molecular remission of Ph mixed phenotype acute leukaemia with minimal residual disease

Kong D, Qu C, Dai H, Li Z, Yin J, Chen S, Kang L, Chen G, Zhu M, Yu L, Wu D, Tang X.

  Br J Haematol. 2020 Jul 22. doi: 10.1111/bjh.16982.


Allogeneic haematopoietic stem cell transplantation improves outcome of adults with relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia entering remission following CD19 chimeric antigen receptor T cells

Gu B, Shi BY, Zhang X, Zhou SY, Chu JH, Wu XJ, Fu CC, Qiu HY, Han Y, Chen SN, Yu L, Ma X, Wu DP.

  Bone Marrow Transplant. 2020 Jun 24. doi: 10.1038/s41409-020-0982-6.


Interleukin-6-knockdown of chimeric antigen receptor-modified T cells significantly reduces IL-6 release from monocytes

Kang L, Tang X, Zhang J, Li M, Xu N, Qi W, Tan J, Lou X, Yu Z, Sun J, Wang Z, Dai H, Chen J, Lin G, Wu D, Yu L.

  Exp Hematol Oncol. 2020 Jun 8;9:11. doi: 10.1186/s40164-020-00166-2. eCollection 2020.


Characterization of novel dual tandem CD19/BCMA chimeric antigen receptor T cells to potentially treat multiple myeloma

Kang L, Zhang J, Li M, Xu N, Qi W, Tan J, Lou X, Yu Z, Sun J, Wang Z, Fu C, Tang X, Dai H, Chen J, Wu D, Yu L.

  Biomark Res. 2020 May 13;8:14. doi: 10.1186/s40364-020-00192-6.


Successful treatment of acute B lymphoblastic leukemia relapse in the skin and testicle by anti-CD19 CAR-T with IL-6 knocking down: a case report.

Liu ZF, Chen LY, Wang J, Kang LQ, Tang H, Zhou Y, Zhou HX, Sun AN, Wu DP, Xue SL.

  Biomark Res.2020 May 6;8:12.doi: 10.1186/s40364-020-00193-5.


Treatment response, survival, safety, and predictive factors to chimeric antigen receptor T cell therapy in Chinese relapsed or refractory B cell acute lymphoblast leukemia patients.

Li L, Liu J, Xu M, Yu H, Lv C, Cao F, Wang Z, Fu Y, Zhang M, Meng H, Zhang X, Kang L, Zhang Z, Li J, Feng J, Lian X, Yu L, Zhou J.

  Cell Death Dis. 2020 Mar 30;11(3):207. doi: 10.1038/s41419-020-2388-1.


Sequential Infusion of Anti-CD22 and Anti-CD19 Chimeric Antigen Receptor T Cells for a Pediatric Ph-Like B-ALL Patient That Relapsed After CART-Cell and Haplo-HSCT Therapy: A Case Report and Review of Literature.

Hua J, Qian W, Wu X, Zhou L, Yu L, Chen S, Zhang J, Qiu H.

  Onco Targets Ther. 2020 Mar 17;13:2311-2317. doi: 10.2147/OTT.S235882.


Anti-CD19 chimeric antigen receptor T-cells induce durable remission in relapsed Philadelphia chromosome-positive ALL with T315I mutation.

Yang F, Yang X, Bao X, Kang L, Zhou L, Wu X, Tang X, Fu Z, Ma X, Sun A, Zhang J, Qiu H, Wu D.

  Leuk Lymphoma. 2020 Feb;61(2):429-436. doi: 10.1080/10428194.2019.1663417.


Inhibition of Cholesterol Esterification Enzyme Enhances the Potency of Human Chimeric Antigen Receptor T Cells against Pancreatic Carcinoma.

Zhao L, Liu Y, Zhao F, Jin Y, Feng J, Geng R, Sun J, Kang L, Yu L, Wei Y.

  Mol Ther Oncolytics.2020 Feb 4;16:262-271. doi: 10.1016/j.omto.2020.01.008.


Successful treatment of marrow failure after CARTs for myeloma by the infusion of cryopreserved stem cells.

Yan L, Shang J, Shi X, Kang H, Liu W, Xu N, Liu Y, Chen G, Kang L, Gong F, Tang F, Yu L, Wu D, Fu C.

  Am J Hematol. 2020 Jan;95(1):E20-E23. doi: 10.1002/ajh.25664.


Radiation Priming Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma With High Tumor Burden.

Qu C, Ping N, Kang L, Liu H, Qin S, Wu Q, Chen X, Zhou M, Xia F, Ye A, Kong D, Li C, Yu L, Wu D, Jin Z.

  J Immunother. 2020 Jan;43(1):32-37.doi: 10.1097/CJI.0000000000000284.


2019年:

Donor origin CAR19 T cell infusion for B-ALL relapsed after allogeneic hematopoietic stem cell transplantation.

Yang X, Dai H, Kang L, Qu C, Li Z, Yin J, Qiu H, Fu C, Han Y, Jin Z, Ma X, Zhu X, Yu L, Wu D, Tang X.

  Hematol Oncol. 2019 Dec;37(5):655-658. doi: 10.1002/hon.2682.


Successful chimeric antigen receptor T cell therapy in a case of primary testicular diffuse large-B-cell lymphoma with central nervous system progression.

Ping N, Qu C, Bai L, Kang L, Chen X, Wu Q, Xia F, Yu L, Yao H, Wu D, Jin Z.

  Leuk Lymphoma. 2019 Nov;60(11):2814-2816. doi: 10.1080/10428194.2019.1605507.


Allogeneic CAR-T for treatment of relapsed and/or refractory multiple myeloma: four cases report and literatures review.

Yan LZ, Shang JJ, Shi XL, Qu S, Kang LQ, Xu N, Chang WR, Yu L, Wu DP, Fu CC.

  Zhonghua Xue Ye Xue Za Zhi. 2019 Aug 14;40(8):650-655.


Successful treatment of two relapsed/refractory t(8;21) acute myeloid leukemia patients by CD19-directed chimeric antigen receptor T cells.

Qu C, Li Z, Kang L, Wang Y, Dai H, Yin J, Chen G, Zhu M, Yao L, Xu T, Tian X, Xu Y, Chen J, Zhu X, Yu L, Wu D, Tang X.

  Bone Marrow Transplant. 2019 Jul;54(7):1138-1140. doi: 10.1038/s41409-018-0423-y.


Comparation of CART19 and autologous stem-cell transplantation for refractory/relapsed non-Hodgkin's lymphoma.

Li C, Zhang Y, Zhang C, Chen J, Lou X, Chen X, Kang L, Xu N, Li M, Tan J, Sun X, Zhou J, Yang Z, Zong X, Wang P, Xu T, Qu C, Huang H, Jin Z, Yu L, Wu D.

  JCI Insight. 2019 Jul 23;5(17):e130195. doi: 10.1172/jci.insight.130195.


Delayed remission following sequential infusion of humanized CD19- and CD22-modified CAR-T cells in a patient with relapsed/refractory acute lymphoblastic leukemia and prior exposure to murine-derived CD19-directed CAR-T cells.

Yang F, Zhang J, Zhang X, Tian M, Wang J, Kang L, Qiu H, Wu D.

  Onco Targets Ther.2019 Mar 25;12:2187-2191.doi: 10.2147/OTT.S189103.


2018年:

Cholesterol Esterification Enzyme Inhibition Enhances Antitumor Effects of Human Chimeric Antigen Receptors Modified T Cells.

Zhao L, Li J, Liu Y, Kang L, Chen H, Jin Y, Zhao F, Feng J, Fang C, Zhu B, Ding S, Yu L, Wei Y, Zhou J

  J Immunother. Feb/Mar 2018;41(2):45-52. doi: 10.1097/CJI.0000000000000207.


2017年:

Chimeric?antigen receptors for adoptive T cell therapy in acute myeloid leukemia.

Fan M, Li M, Gao L, Geng S, Wang J, Wang Y, Yan Z, Yu L.

  J Hematol Oncol. 2017 Aug 29;10(1):151. doi: 10.1186/s13045-017-0519-7.